ALK-positive large B-cell lymphoma with strong CD30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib

Histopathology. 2016 Nov;69(5):880-882. doi: 10.1111/his.13002. Epub 2016 Jul 19.

Authors

Varun Mehra¹, Sabine Pomplum², Robin Ireland¹, Deborah Yallop¹, Stephen Devereux¹, Robert Marcus¹, Chirag Shah³, Piers Patten¹, Shireen Kassam¹

Affiliations

¹ Department of Haematology, King's College Hospital, London, UK.
² Department of Histopathology, University College Hospital, London, UK.
³ Department of Histopathology, King's College Hospital, London, UK.

PMID: 27238948
DOI: 10.1111/his.13002

No abstract available

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / therapeutic use*
Brentuximab Vedotin
Crizotinib
Diagnostic Errors
Drug Resistance, Neoplasm
Fatal Outcome
Female
Humans
Immunoconjugates / therapeutic use
In Situ Hybridization, Fluorescence
Lymphoma, Large B-Cell, Diffuse / diagnosis*
Lymphoma, Large-Cell, Anaplastic / diagnosis*
Lymphoma, Large-Cell, Anaplastic / drug therapy
Pyrazoles / therapeutic use
Pyridines / therapeutic use
Young Adult

Substances

Antineoplastic Agents
Immunoconjugates
Pyrazoles
Pyridines
Crizotinib
Brentuximab Vedotin